Lilly’s Q2 Smashes Estimates, Yet the Stock Barely Budges in 2026

Life Science

5 High-Dividend Value Stocks to Buy as Market Valuations Stretch to Extremes

Consumer Goods, Life Science, Real Estate, Technology

Medtronic Could Rally 40% by Year-End, With Dividend King Status on the Horizon

Life Science

Vertex Tops Q2 Estimates, But Investors Shift Focus to Crinetics Deal Integration

Life Science

AbbVie Lowers Full-Year Profit Guidance, Investor Disappointment Triggers Stock Sell-Off

Life Science

Novo Nordisk: At 11x P/E, a Golden Entry or a Value Trap?

Life Science

Bristol-Myers Squibb Beats Estimates in Q2, Stock Outperforms Market on Thursday

Life Science

Weight-Loss Pipeline in Focus: Viking Therapeutics Could Be the Next Acquisition Target

Life Science

Seize the Golden Window for Biotech IPOs, Attovia Aims to Raise Up to $212.5 Million in Nasdaq Debut

Life Science

Johnson & Johnson Quietly Completes Strategic Pivot, Targeting $50 Billion Cancer Drug Blueprint

Life Science

Can Amgen’s Monthly Obesity Shot Rattle the Eli Lilly-Novo Nordisk Duopoly?

Life Science

Intuitive Surgical Down 44%: Wall Street Eyes a Double-Your-Money Rebound

Life Science, Technology

After a 1,930% Decade, Should You Chase SMH or Rotate into SCHD?

Financial Service, Life Science, Technology

Capital Expenditure Surge Reshapes Market Landscape as Funds Flee Tech Stocks for Value Opportunity in Healthcare

Life Science, Technology

Moderna’s Market Value Exceeds Twenty Billion Dollars, Yet Ongoing Operating Losses and Competitive Pressures Continue to Trouble Investors

Life Science